PrEP is the preventive HIV medication used to lower infection risk in high‑risk populations; current news centers on funding gaps and expansion efforts.
Donor contributions to HIV programmes have declined, with the 2025 funding level the lowest since 2007. The US remains the largest donor but has reduced its support, while total resources for HIV response have fallen 18% across all sources. UNAIDS warns that declining funding could jeopardise gains in prevention and treatment in Sub-Saharan Africa.
Fiji has declared a national health emergency after HIV infections have surged: new diagnoses reached about 2,016 in 2025 and an estimated 9,100 people were living with HIV. Only 39% knew their status and 22% were on antiretroviral treatment; the government has pledged expanded testing, free treatment, needle-and-syringe programmes and PrEP scale-up.